Antibodies for Treatment of Clostridium difficile Infection

Human Monoclonal Antibodies against Clostridium difficile Toxins A and B Inhibit Inflammatory and Histologic Responses to the Toxins in Human Colon and Peripheral Blood Monocytes

(2013) Hon Wai Koon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Mixture of Functionally Oligoclonal Humanized Monoclonal Antibodies That Neutralize Clostridium difficile TcdA and TcdB with High Levels ofIn VitroPotency ShowsIn VivoProtection in a Hamster Infection Model

(2013) Nicola L. Davies et al.   Clinical and Vaccine Immunology

Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile Infection

(2013) A. Sarah Walker et al.   CLINICAL INFECTIOUS DISEASES

In VivoPhysiological and Transcriptional Profiling Reveals Host Responses to Clostridium difficile Toxin A and Toxin B

(2013) Kevin M. D'Auria et al.   INFECTION AND IMMUNITY

Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments

(2013) Rosanna Leuzzi et al.   INFECTION AND IMMUNITY

Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B fromClostridium difficile

(2013) Tomohiko Murase et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Importance of Toxin A, Toxin B, and CDT in Virulence of an Epidemic Clostridium difficile Strain

(2013) Sarah A. Kuehne et al.   JOURNAL OF INFECTIOUS DISEASES

Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection

(2013) Timothy D Planche et al.   LANCET INFECTIOUS DISEASES

Circulating Antibody and Memory B-Cell Responses to C. difficile Toxins A and B in Patients with C. difficile-Associated Diarrhoea, Inflammatory Bowel Disease and Cystic Fibrosis

(2013) Tanya M. Monaghan et al.   PLoS One

Clostridium difficile Binary Toxin CDT Induces Clustering of the Lipolysis-Stimulated Lipoprotein Receptor into Lipid Rafts

(2013) P. Papatheodorou et al.   mBio

Potent monoclonal antibodies againstClostridium difficiletoxin A elicited by DNA immunization

(2013) Chunhua Zhang et al.   Human Vaccines & Immunotherapeutics

Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB

(2013) Jordi M. Lanis et al.   PLoS Pathogens

Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy Subjects

(2012) Stephen A. Villano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recombinant antibody mixtures: Production strategies and cost considerations

(2012) Søren K. Rasmussen et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

IgG Antibody Response to Toxins A and B in Patients with Clostridium difficile Infection

(2012) M. Wullt et al.   Clinical and Vaccine Immunology

Burden of Clostridium difficile on the Healthcare System

(2012) Erik R. Dubberke et al.   CLINICAL INFECTIOUS DISEASES

A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection

(2012) Haiying Wang et al.   INFECTION AND IMMUNITY

Predicting Recurrence of C. difficile Colitis Using Bacterial Virulence Factors: Binary Toxin Is the Key

(2012) David B. Stewart et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile Disease

(2012) Jennifer Steele et al.   JOURNAL OF INFECTIOUS DISEASES

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

(2012) Andre J. Marozsan et al.   JOURNAL OF INFECTIOUS DISEASES

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

(2012) Jing-Hui Tian et al.   VACCINE

Protective antibody responses againstClostridium difficileelicited by a DNA vaccine expressing the enzymatic domain of toxin B

(2012) Ke Jin et al.   Human Vaccines & Immunotherapeutics

Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype

(2012) Siu-Kei Chow et al.   Toxins

The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital

(2011) A. J. Forster et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Development and Evaluation of an Ovine Antibody-Based Platform for Treatment of Clostridium difficile Infection

(2011) April Roberts et al.   INFECTION AND IMMUNITY

Mouse Relapse Model of Clostridium difficile Infection

(2011) Xingmin Sun et al.   INFECTION AND IMMUNITY

Neutralization ofClostridium difficileToxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain

(2011) Greg Hussack et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic Dissemination of Clostridium difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal Models

(2011) Jennifer Steele et al.   JOURNAL OF INFECTIOUS DISEASES

Efficient mucosal vaccination mediated by the neonatal Fc receptor

(2011) Lilin Ye et al.   NATURE BIOTECHNOLOGY

Differential Binding and Internalization of Clostridium difficile Toxin A by Human Peripheral Blood Monocytes, Neutrophils and Lymphocytes

(2011) N. Modi et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Intravenous immunoglobulin for the treatment of severeClostridium difficilecolitis: An observational study and review of the literature

(2010) Marwan S. Abougergi et al.   Journal of Hospital Medicine

Clostridium difficile infection in Europe: a hospital-based survey

(2010) Martijn P Bauer et al.   LANCET

Neutralization ofClostridium difficiletoxin A using antibody combinations

(2010) Stephen J. Demarest et al.   mAbs

The role of toxin A and toxin B in Clostridium difficile infection

(2010) Sarah A. Kuehne et al.   NATURE

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variations in TcdB Activity and the Hypervirulence of Emerging Strains of Clostridium difficile

(2010) Jordi M. Lanis et al.   PLoS Pathogens

Antibody-Enhanced, Fc Gamma Receptor-Mediated Endocytosis of Clostridium difficile Toxin A

(2009) X. He et al.   INFECTION AND IMMUNITY

Antibody Protection against Botulinum Neurotoxin Intoxication in Mice

(2009) L. W. Cheng et al.   INFECTION AND IMMUNITY

An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins

(2009) Xiangyun He et al.   JOURNAL OF MICROBIOLOGICAL METHODS

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A

(2009) David F. Gardiner et al.   VACCINE

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium

(2009) Richard A Stabler et al.   GENOME BIOLOGY

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences

(2008) R. A. Stabler et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Dependence of antibody-mediated presentation of antigen on FcRn

(2008) S.-W. Qiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A

(2008) Claribel P. Taylor et al.   VACCINE